Kolon Life Science Inc.

Yongin si, South Korea

Kolon Life Science Inc.

Yongin si, South Korea
SEARCH FILTERS
Time filter
Source Type

Lee J.H.,Korea University | You S.,Gangneung - Wonju National University | Kweon D.-K.,Kolon Life Science Inc. | Chung H.-J.,Chonnam National University | Lim S.-T.,Korea University
Food Hydrocolloids | Year: 2014

Dissolution behavior and molecular conformation of waxy maize amylopectin in aqueous DMSO solutions containing different amounts of water and salts (NaCl or CaCl2 up to 0.2M) were characterized using multi-angle laser light scattering (MALLS; micro-batch mode) and dynamic light scattering (DLS) detectors. The solubility of amylopectin decreased and the molecular size measured increased when the water content in the DMSO increased, indicating that amylopectin chains tended to be less dissociated or aggregate by the excess amount of water. The amylopectin in aqueous DMSO solutions (10-50% water) had a spherical shape with a regular star structure, but the individual amylopectin chains were not affected by water content. Minor addition of salts facilitated the dissolution of amylopectin in aqueous DMSO solutions, possibly due to water cluster formation by the salt ions. However, a minute presence of salts (0.01 and 0.05M) could induce the chain association even in 90% DMSO solution. © 2013 Elsevier Ltd.


Ha C.-W.,Sungkyunkwan University | Noh M.J.,TissueGene Inc. | Choi K.B.,Kolon Life Science Inc. | Lee K.H.,TissueGene Inc. | Lee K.H.,Inha University
Cytotherapy | Year: 2012

Background aims. TissueGene-C (TG-C) represents a cell-mediated gene therapy for localized delivery of allogeneic chondrocytes expressing transforming growth factor (TGF)-β1 directly to the damaged knee joint. Untransduced human chondrocytes (hChonJ cells) have also been incorporated into the TG-C product at a 3:1 ratio with TGF-β1-expressing chondrocytes (hChonJb#7) in order to help fill in the defect and as target cells for the actions of the expressed TGF-β1. Methods. A phase I dose-escalating clinical trial was performed to evaluate the safety and biologic activity of TG-C in patients with advanced osteoarthritis of the knee joint (full thickness cartilage defect) that was refractory to existing non-operative therapies. Following a single intra-articular injection into the joint space of the damaged knee, patients were monitored for safety, and an evaluation was performed to assess the pharmacokinetics and biologic activity of TG-C. Results. There were no treatment-related serious adverse events. Swelling, effusion and minor localized reactions such as warming sensation or itching were observed in a dose-dependent manner at the injection site. Knee evaluation scores seemed to indicate a dose-dependent trend toward efficacy; however, patient numbers were not sufficient to determine statistical significance. Conclusions. Overall, there were no significant safety issues related to the administration of TG-C, with only some minor injection site reactions observed. Additionally, knee scoring analyzes indicated a possibility that TG-C may contribute to improvement of arthritic symptoms. More study is warranted to evaluate further the safety and determine the potential efficacy of TG-C. © 2012 Informa Healthcare.


Kim T.,Kolon Life Science Inc. | Kim K.,Seoul National University
Tetrahedron Letters | Year: 2010

Treatment of β-aryl-β-(benzotriazol-1-yl)-α-primary alkyl (or aryl)-α,β-unsaturated ketones 1 with n-Bu3SnH (4 equiv) in a catalytic amount of AIBN in PhH at reflux afforded 3-alkyl (or aryl)-2-arylindoles 8 in good yields. However, when tert-butyl group is bonded at α-position, 3-acyl (or aroyl)-2-arylindoles 9 were obtained as major products along with phenanthridines 5 as minor products. © 2009 Elsevier Ltd. All rights reserved.


Choi J.-i.,Korea Atomic Energy Research Institute | Kim J.-K.,Korea Atomic Energy Research Institute | Kim J.-H.,Korea Atomic Energy Research Institute | Kweon D.-K.,Kolon Life Science Inc. | Lee J.-W.,Korea Atomic Energy Research Institute
Carbohydrate Polymers | Year: 2010

In this study, high molecular weight hyaluronic acid in powder form (HMW-HA, with average molecular weight of 1042 kDa) was degraded to low molecular (LMW-HA, 200-230 kDa) by several methods, and the changes in molecular structure and antioxidative activities brought about by each degradation method were compared. The degradation methods used were electron beam irradiation (EB), gamma ray irradiation (GM), microwave irradiation (MW), and thermal treatment (TH). The FT-IR spectra showed no substantial changes of the spectral pattern between HMW and LMW-HAs. However, the UV absorbance of LMW-HA by MW was considerably greater at 265 nm indicating the formation of more double bonds. The antioxidative activities of all LMW-HA samples were found to have risen, but the MW-treated LMW-HA showed the most significant increase due to a newly formed double bond. EB- and GM-treated LMW-HA showed the lowest polydispersity and little change in UV spectra from those of HMW-HA. © 2009 Elsevier Ltd. All rights reserved.


Kim T.,Kolon Life Science Inc. | Kim K.,Seoul National University
Journal of Heterocyclic Chemistry | Year: 2010

(Chemical Equation Presented) Treatment of 1-(2-azidoarylmethyl)-1H- benzotriazoles (6) with n-BuLi (2.5 equiv.) in THF at -78°C, followed by an addition of alkyl halides such as allyl, benzyl, and ethyl bromides with stirring for 2 h at room temperature afforded 2-(dialkylamino)-3-(benzotriazol- 1-yl)-2H-indazoles (8), 3-(benzotriazol-1-yl)-2H-indazoles (9), 2-[(benzotriazol-1-yl)methyl]arylamine (10), and 2-[(benzotriazol-1-yl)(alkyl) methyl]arylamine (11). © 2009 HeteroCorporation.


Rhee K.H.,Kongju National University | Lee K.H.,Kolon Life Science Inc.
Natural Product Sciences | Year: 2011

It has been shown that the butanol extract of Lonicera japonica has antimicrobial and other potentially useful biological activities. The purpose of this study was to determine the in vitro activity of Lonicera japonica compared to other antimicrobial agents against anaerobic bacteria. Specifically, the in vitro activity of the butanol extract was investigated against 104 clinical isolates of anaerobic bacteria using an agar dilution method and the results were compared to erythromycin, cefoxitin, imipenem, clindamycin, and metronidazole. It was found that Lonicera japonica and imipenem were the most active antimicrobial agents tested.


Lee K.-H.,Kolon Life Science Inc. | Kim G.-W.,Kongju National University | Rhee K.-H.,Kongju National University
Journal of Microbiology and Biotechnology | Year: 2010

The Actinomycete strain KH29 is antagonistic to the multidrug-resistant Acinetobacter baumannii. Based on the diaminopimelic acid (DAP) type, and the morphological and physiological characteristics observed through the use of scanning electron microscopy (SEM), KH29 was confirmed as belonging to the genus Streptomyces. By way of its noted 16S rDNA nucleotide sequences, KH29 was found to have a relationship with Streptomyces cinnamonensis. The production of an antibiotic from this strain was found to be most favorable when cultured with glucose, polypeptone, and yeast extract (PY) medium for 6 days at 27°C. The antibiotic produced was identified, through comparisons with reported spectral data including MS and NMR as a cyclo(L-tryptophanyl-L-tryptophanyl). Cyclo(L-Trp-L-Trp), from the PY cultures of KH29, was seen to be highly effective against 41 of 49 multidrugresistant Acinetobacter baumannii. Furthermore, cyclo(LTrp-L-Trp) had antimicrobial activity against Bacillus subtilis, Micrococcus luteus, Staphylococcus aureus, Saccharomyces cerevisiae, Aspergillus niger, and Candida albicans, However, it was ineffective against Streptomyces murinus.


Rhee K.H.,Kongju National University | Lee K.H.,Kolon Life Science Inc.
Archives of Pharmacal Research | Year: 2011

Fucoidan, a sulfated polysaccharide purified from brown algae including Fucus vesiculosus and Laminaria japonica, has a variety of biological activities, including antioxidant and antitumor activities. Here, we investigated the radioprotective effects of fucoidan on human monoblastic leukemia cell line U937. Further, animal tests were carried out using Balb/c mice in order to determine the radiation-induced changes in the counts of blood cells, including thrombocytes, erythrocytes, leukocytes and hematocrit. Cell viability was assessed by the 3-(4,5- dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide assay, wherein fucoidan (1, 10, and 100 μg/mL) was observed to improve recovery from damage caused by 8-Gy radiation in a dose dependent manner. The viability of U937 cells pre-treated with fucoidan also increased in a dose dependent manner. Furthermore, fucoidan at 100 mg/kg was found to protect against changes in the counts of blood cells as follows: on day 28 after irradiation, the thrombocyte count in the irradiated controls decreased to 45% compared with the non-irradiated controls, while that in the fucoidan-treated group was 60%. The hematocrit in the fucoidan-treated group recovered to 75% on day 28, while that in the irradiated control was 68%. The erythrocyte count in the irradiated controls consistently ranged from 64% to 67% throughout the experiment, but that in the fucoidan-treated group increased gradually, ranging from 75% to 80%. The mean number of survival days and 50-day actuarial survival rate increased dose dependently in the fucoidan-treated group. The mean number of survival days and the 50-day actuarial survival rate in this group was 16, 21, and 29 days and 12%, 20%, and 30% at fucoidan doses of 1, 10, and 100 mg/kg. The values of these parameters in the control group were 9 days and 0%, although the difference between the test and control groups was not statistically significant. Our results may prove valuable in the field of radioprotection. Copyright © 2011 American Society of Nuclear Cardiology.


Patent
Kolon Life Science Inc. | Date: 2010-05-14

The present invention provides a method of preparing an alkylamine derivates which hardly generates impurities and enables mass production with high purity.


Trademark
Kolon Life Science Inc. | Date: 2011-11-02

Antimicrobial preparations, namely, preparations for inhibiting microbiological, especially fungal, growth in personal care products and industrial products; Antiseptic preparations; Pharmaceutical preparations for treating dandruff; Insect repellents; Germicides; Herbicides; Insecticides; Disinfectants for hygiene purposes.

Loading Kolon Life Science Inc. collaborators
Loading Kolon Life Science Inc. collaborators